Published in N Engl J Med on August 27, 1998
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
The United Kingdom Childhood Cancer Study: objectives, materials and methods. UK Childhood Cancer Study Investigators. Br J Cancer (2000) 2.37
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA (2015) 2.20
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood (2008) 2.17
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood (2007) 1.97
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol (2015) 1.74
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood (2007) 1.53
Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission. Oman J Ophthalmol (2010) 1.44
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer (2008) 1.40
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood (2008) 1.34
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer (2007) 1.31
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia (2009) 1.27
Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood (2010) 1.17
Clinical trials in the era of personalized oncology. CA Cancer J Clin (2011) 1.13
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma (2009) 1.13
Mutagenic and cytotoxic properties of 6-thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid. J Biol Chem (2008) 1.11
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer (2010) 1.09
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol (2013) 1.07
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant (2011) 1.06
Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report. Biol Blood Marrow Transplant (2007) 1.05
Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett (2013) 1.04
AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther (2011) 1.03
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica (2014) 1.02
Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I. J Mol Biol (2007) 1.01
6-Thioguanine and S⁶-methylthioguanine are mutagenic in human cells. ACS Chem Biol (2010) 1.01
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer (2003) 0.98
Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer (2005) 0.97
Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res (2010) 0.96
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood (2013) 0.95
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer (2008) 0.94
6-Thioguanine perturbs cytosine methylation at the CpG dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo. Biochemistry (2009) 0.93
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 0.93
Inter-platform comparability of microarrays in acute lymphoblastic leukemia. BMC Genomics (2004) 0.93
Early lymphocyte recovery as a predictor of outcome, including relapse, after hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter (2012) 0.92
Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2001) 0.91
On systems and control approaches to therapeutic gain. BMC Cancer (2006) 0.90
Recent advances in management of acute leukaemia. Arch Dis Child (2000) 0.89
LC-MS/MS coupled with stable isotope dilution method for the quantification of 6-thioguanine and S(6)-methylthioguanine in genomic DNA of human cancer cells treated with 6-thioguanine. Anal Chem (2010) 0.89
Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs (2011) 0.89
Parental occupational pesticide exposure and the risk of childhood leukemia in the offspring: findings from the childhood leukemia international consortium. Int J Cancer (2014) 0.88
Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol (2010) 0.87
LMO2 at 25 years: a paradigm of chromosomal translocation proteins. Open Biol (2015) 0.86
Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci (2012) 0.86
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep (2013) 0.86
VE-cadherin and PECAM-1 enhance ALL migration across brain microvascular endothelial cell monolayers. Exp Hematol (2010) 0.84
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol (2014) 0.83
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma (2010) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol (2013) 0.83
The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 0.82
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther (2011) 0.82
Aptamer-based and DNAzyme-linked colorimetric detection of cancer cells. Protein Cell (2010) 0.80
Effects of Toll-like receptor signals in T-cell neoplasms. Future Oncol (2011) 0.79
Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution. J Korean Med Sci (2009) 0.79
Characterization of acute lymphoblastic leukemia subtypes in moroccan children. Int J Pediatr (2009) 0.78
A unique complex translocation involving six different chromosomes in a case of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and adverse prognosis. Oncol Lett (2010) 0.77
Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens. Mediterr J Hematol Infect Dis (2013) 0.77
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. Adv Hematol (2011) 0.77
Potential toxicities of prophylactic cranial irradiation. Transl Lung Cancer Res (2012) 0.77
Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia. Clin Pharmacol Ther (2010) 0.76
Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag (2007) 0.76
Molecular cytogenetics in childhood acute lymphoblastic leukemia: a hospital-based observational study. Clin Med Insights Oncol (2015) 0.76
Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia (2016) 0.76
Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome. PLoS One (2016) 0.75
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther (2016) 0.75
Emerging technologies in paediatric leukaemia. Transl Pediatr (2015) 0.75
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review. Ont Health Technol Assess Ser (2016) 0.75
Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemia. Mol Clin Oncol (2015) 0.75
Sinonasal Lymphoma Presenting as a Probable Sanctuary Site for Relapsed B Acute Lymphoblastic Leukaemia: A Case Report and Review of the Literature. Case Rep Hematol (2015) 0.75
6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells. BMC Vet Res (2014) 0.75
Prognostic significance of cell surface phenotype in acute lymphoblastic leukemia. South Asian J Cancer (2015) 0.75
Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report. J Med Case Rep (2017) 0.75
Retrovirus-transformed erythroleukemia cells induce central nervous system failure in a new syngeneic mouse model of meningeal leukemia. Leuk Res (2011) 0.75
Prevalence of ETV6/RUNX1 Fusion Gene in Pediatric Patients with Acute Lymphoblastic Leukemia in Iran. Iran J Pediatr (2013) 0.75
Therapeutic trials in childhood ALL: what's their future? J Clin Pathol (2000) 0.75
Remission of lymphoblastic leukaemia in an intravascular fluidic environment by pliable drug carrier with a sliding target ligand. Sci Rep (2017) 0.75
Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis (2014) 0.75
Down syndrome with microgranular variant of acute promyelocytic leukemia in a child: a case report. J Med Case Rep (2007) 0.75
PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biol Ther (2013) 0.75
ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis (2016) 0.75
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer (2017) 0.75
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Review of small bowel obstruction at Milwaukee County General Hospital. Am J Surg (1966) 1.56
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
Determination of viability of ischemic intestine by Doppler ultrasound. Surgery (1978) 1.54
Bypass grafting to distal arteries for limb salvage. Surg Gynecol Obstet (1972) 1.54
Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther (1994) 1.51
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther (1992) 1.51
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics (1996) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol (1994) 1.48
Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol (2001) 1.48
Cardiovascular risk factors in patients with peripheral vascular disease. Surgery (1978) 1.44
Acute suppurative cholangitis. Experience with 15 consecutive cases. Arch Surg (1967) 1.43
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol (1991) 1.42
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia (2010) 1.34
The effects of "cell age" upon the lethal effects of physical and chemical mutagens in the yeast, Saccharomyces cerevisiae. Mol Gen Genet (1976) 1.34
A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet (1995) 1.33
Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet (1998) 1.31
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 1.29
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood (1994) 1.29
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest (1994) 1.29
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 1.29
Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol (2000) 1.28
Blind river dolphin: first side-swimming cetacean. Science (1969) 1.25
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood (1996) 1.24
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol (1997) 1.23
Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet (2000) 1.21
Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood (1997) 1.18
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia (1997) 1.18
Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol (1995) 1.15
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
Nonparasitic splenic cysts. Case report of epidermoid cyst with review of the literature. Am J Surg (1973) 1.14
Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia (1998) 1.14
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol (1996) 1.14
Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology (2000) 1.13
Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol (1988) 1.11
Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther (2007) 1.11
Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics (1999) 1.11
Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr (1987) 1.10
ORAL PENICILLIN WITH BASIC ALUMINUM AMINOACETATE. Science (1945) 1.10
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10
A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol (2001) 1.10
Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet (1984) 1.10
Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood (1999) 1.09
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia (2011) 1.08
Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr (1994) 1.07
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia (2009) 1.07
Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood (1992) 1.05
Lead poisoning from ingestion of Chinese herbal medicine. Clin Toxicol (1977) 1.04
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (1995) 1.04
Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos (1995) 1.04
TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol (1997) 1.04
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther (1991) 1.03
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther (1991) 1.02
Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet (1994) 1.01
Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia (1998) 1.01
Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res (1999) 1.01
Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med (1995) 1.01
Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol (1996) 1.00
Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol (1999) 1.00
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia (2012) 1.00
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia (1998) 1.00
Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther (1994) 0.99
Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. Cancer (1990) 0.99
Therapeutic drug monitoring in cancer management. Clin Chem (1993) 0.99
Granuloma (sarcoid?) of the pancreas. A case report. Am J Gastroenterol (1978) 0.97
Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum (1991) 0.97
Intraoperative localization of intestinal arteriovenous malformation. Arch Surg (1978) 0.97
Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem (1998) 0.97